PACIRA BIOSCIENCES, INC. Restructuring Costs
PACIRA BIOSCIENCES, INC. (PCRX) reported Restructuring Costs of $5.54 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2024-05-07
- PACIRA BIOSCIENCES, INC. restructuring costs for the quarter ending 2024-03-31 was $5.54M.
- PACIRA BIOSCIENCES, INC. restructuring costs for the quarter ending 2023-03-31 was $0.00.
| Period end | Restructuring Costs 3 month |
|---|---|
| 2024-03-31 | $5.54M 10-Q · filed 2024-05-07 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |